Symbols / CTOR $0.69 -1.83% Citius Oncology, Inc.
CTOR Chart
About
Citius Oncology, Inc. focuses on the development and commercialization of innovative targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. is a subsidiary of Leonard-Meron Biosciences, Inc.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Drug Manufacturers - Spe | Market Cap | 60.92M |
| Enterprise Value | 58.56M | Income | -23.64M | Sales | 3.94M |
| Book/sh | 0.69 | Cash/sh | 0.08 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | — | PEG | — |
| P/S | 15.45 | P/B | 1.00 | P/C | — |
| EV/EBITDA | — | EV/Sales | 14.85 | Quick Ratio | 0.25 |
| Current Ratio | 0.83 | Debt/Eq | 6.51 | LT Debt/Eq | — |
| EPS (ttm) | -0.31 | EPS next Y | — | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-02-13 08:00 | ROA | -13.96% |
| ROE | -47.41% | ROIC | — | Gross Margin | 79.99% |
| Oper. Margin | -133.17% | Profit Margin | 0.00% | Shs Outstand | 88.28M |
| Shs Float | 14.13M | Short Float | 4.69% | Short Ratio | 2.57 |
| Short Interest | — | 52W High | 6.19 | 52W Low | 0.49 |
| Beta | 3.43 | Avg Volume | 273.09K | Volume | 56.73K |
| Target Price | $6.00 | Recom | None | Prev Close | $0.70 |
| Price | $0.69 | Change | -1.83% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$6.00
Mean price target
2. Current target
$0.69
Latest analyst target
3. DCF / Fair value
$-5.04
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.69
Low
$6.00
High
$6.00
Mean
$6.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-09-23 | up | Maxim Group | Hold → Buy | $6 |
| 2025-05-23 | down | Maxim Group | Buy → Hold | — |
| 2024-11-27 | init | Maxim Group | — → Buy | $3 |
| 2024-08-13 | main | EF Hutton | Buy → Buy | $6 |
- CTOR Stock Price, Quote & Chart | CITIUS ONCOLOGY INC (NASDAQ:CTOR) - ChartMill Wed, 01 Apr 2026 07
- CTOR Stock Price and Chart — NASDAQ:CTOR - TradingView Mon, 16 Mar 2026 07
- Cancer centers move LYMPHIR onto formularies as coverage reaches 80% - Stock Titan ue, 31 Mar 2026 13
- Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules - PR Newswire ue, 09 Dec 2025 08
- Citius Oncology (CTOR) expands Lymphir distribution to Europe through exclusive agreement with Uniphar - msn.com Wed, 18 Mar 2026 15
- CTOR Tests Key Support With Weak Volume and Modest RSI Rebound - Bitget hu, 02 Apr 2026 07
- Citius Oncology, Inc. (NASDAQ:CTOR) stock most popular amongst public companies who own 79%, while individual investors hold 14% - Yahoo Finance Fri, 26 Sep 2025 07
- Citius Oncology highlights early LYMPHIR commercial traction, expansion - TipRanks Wed, 01 Apr 2026 03
- Citius Oncology (NASDAQ:CTOR) Trading Down 2.8% - Here's What Happened - MarketBeat ue, 24 Mar 2026 07
- When Will Citius Oncology, Inc. (NASDAQ:CTOR) Become Profitable? - Yahoo Finance hu, 06 Nov 2025 08
- Citius drug combo shows tumor responses in hard-to-treat gynecologic cancers - Stock Titan ue, 10 Mar 2026 07
- Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™ - PR Newswire Fri, 13 Feb 2026 08
- Uniphar to offer LYMPHIR via access programs for CTCL in Europe - Stock Titan Wed, 11 Feb 2026 08
- Early lymphoma trial tests LYMPHIR before CAR-T, sees 86% response rate - Stock Titan Wed, 04 Mar 2026 08
- Citius Oncology Signs U.S. Distribution Agreement with McKesson to Support LYMPHIR™ Commercial Launch - Stock Titan Mon, 20 Oct 2025 07
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
23.52
+14.34%
|
20.57
+69.72%
|
12.12
+149.58%
|
4.86
|
| Research And Development |
|
6.42
+30.32%
|
4.93
+16.14%
|
4.24
+23.71%
|
3.43
|
| Selling General And Administration |
|
17.10
+9.31%
|
15.65
+98.56%
|
7.88
+451.59%
|
1.43
|
| General And Administrative Expense |
|
17.10
+9.31%
|
15.65
+98.56%
|
7.88
+451.59%
|
1.43
|
| Salaries And Wages |
|
8.32
+10.96%
|
7.50
+281.52%
|
1.97
|
0.00
|
| Other Gand A |
|
8.78
+7.79%
|
8.15
+37.76%
|
5.92
+314.02%
|
1.43
|
| Total Expenses |
|
23.52
+14.34%
|
20.57
+69.72%
|
12.12
+149.58%
|
4.86
|
| Operating Income |
|
-23.52
-14.34%
|
-20.57
-69.72%
|
-12.12
-149.58%
|
-4.86
|
| Total Operating Income As Reported |
|
-23.52
-14.34%
|
-20.57
|
—
|
—
|
| EBITDA |
|
-23.49
-14.16%
|
-20.57
-69.72%
|
-12.12
-149.58%
|
-4.86
|
| Normalized EBITDA |
|
-23.49
-14.16%
|
-20.57
-69.72%
|
-12.12
-149.58%
|
-4.86
|
| EBIT |
|
-23.49
-14.16%
|
-20.57
-69.72%
|
-12.12
-149.58%
|
-4.86
|
| Net Income |
|
-24.76
-17.08%
|
-21.15
-66.56%
|
-12.70
-133.72%
|
-5.43
|
| Pretax Income |
|
-23.70
-15.22%
|
-20.57
-69.72%
|
-12.12
-149.58%
|
-4.86
|
| Net Non Operating Interest Income Expense |
|
-0.18
|
0.00
|
—
|
—
|
| Interest Expense Non Operating |
|
0.22
|
0.00
|
—
|
—
|
| Net Interest Income |
|
-0.18
|
0.00
|
—
|
—
|
| Interest Expense |
|
0.22
|
0.00
|
—
|
—
|
| Interest Income Non Operating |
|
0.04
|
0.00
|
—
|
—
|
| Interest Income |
|
0.04
|
0.00
|
—
|
—
|
| Tax Provision |
|
1.06
+83.50%
|
0.58
+0.00%
|
0.58
+0.00%
|
0.58
|
| Tax Rate For Calcs |
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-24.76
-17.08%
|
-21.15
-66.56%
|
-12.70
-133.72%
|
-5.43
|
| Net Income From Continuing Operation Net Minority Interest |
|
-24.76
-17.08%
|
-21.15
-66.56%
|
-12.70
-133.72%
|
-5.43
|
| Net Income From Continuing And Discontinued Operation |
|
-24.76
-17.08%
|
-21.15
-66.56%
|
-12.70
-133.72%
|
-5.43
|
| Net Income Continuous Operations |
|
-24.76
-17.08%
|
-21.15
-66.56%
|
-12.70
-133.72%
|
-5.43
|
| Normalized Income |
|
-24.76
-17.08%
|
-21.15
-66.56%
|
-12.70
-133.72%
|
-5.43
|
| Net Income Common Stockholders |
|
-24.76
-17.08%
|
-21.15
-66.56%
|
-12.70
-133.72%
|
-5.43
|
| Diluted EPS |
|
-0.34
-9.68%
|
-0.31
-73.93%
|
-0.18
-133.72%
|
-0.08
|
| Basic EPS |
|
-0.34
-9.68%
|
-0.31
-73.93%
|
-0.18
-133.72%
|
-0.08
|
| Basic Average Shares |
|
73.27
+7.66%
|
68.05
-4.47%
|
71.24
+0.00%
|
71.24
|
| Diluted Average Shares |
|
73.27
+7.66%
|
68.05
-4.47%
|
71.24
+0.00%
|
71.24
|
| Diluted NI Availto Com Stockholders |
|
-24.76
-17.08%
|
-21.15
-66.56%
|
-12.70
-133.72%
|
-5.43
|
| Line Item | Trend | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|---|
| Total Assets |
|
100.94
+19.64%
|
84.37
+76.74%
|
47.73
+11.82%
|
42.69
|
| Current Assets |
|
27.54
+151.10%
|
10.97
+41.81%
|
7.73
+187.52%
|
2.69
|
| Cash Cash Equivalents And Short Term Investments |
|
3.92
+3504282.14%
|
0.00
|
0.00
|
0.00
|
| Cash And Cash Equivalents |
|
3.92
+3504282.14%
|
0.00
|
0.00
|
0.00
|
| Inventory |
|
22.29
+169.53%
|
8.27
|
0.00
|
—
|
| Work In Process |
|
11.71
+448.71%
|
2.13
|
—
|
—
|
| Finished Goods |
|
10.58
+72.42%
|
6.13
|
—
|
—
|
| Prepaid Assets |
|
1.33
-50.69%
|
2.70
-65.09%
|
7.73
+187.52%
|
2.69
|
| Total Non Current Assets |
|
73.40
+0.00%
|
73.40
+83.50%
|
40.00
+0.00%
|
40.00
|
| Goodwill And Other Intangible Assets |
|
73.40
+0.00%
|
73.40
+83.50%
|
40.00
+0.00%
|
40.00
|
| Other Intangible Assets |
|
73.40
+0.00%
|
73.40
+83.50%
|
40.00
+0.00%
|
40.00
|
| Total Liabilities Net Minority Interest |
|
56.08
+46.69%
|
38.23
+72.21%
|
22.20
+245.63%
|
6.42
|
| Current Liabilities |
|
49.49
+51.35%
|
32.70
+55.37%
|
21.05
+259.98%
|
5.85
|
| Payables And Accrued Expenses |
|
49.49
+51.35%
|
32.70
+55.37%
|
21.05
+259.98%
|
5.85
|
| Payables |
|
45.40
+38.83%
|
32.70
+57.30%
|
20.79
+334.36%
|
4.79
|
| Accounts Payable |
|
13.23
+256.57%
|
3.71
+187.94%
|
1.29
+1296.42%
|
0.09
|
| Other Payable |
|
22.65
-20.25%
|
28.40
|
—
|
—
|
| Current Accrued Expenses |
|
4.09
|
0.00
-100.00%
|
0.26
-75.58%
|
1.06
|
| Other Current Liabilities |
|
—
|
0.00
|
—
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
6.59
+19.12%
|
5.53
+379.87%
|
1.15
+100.00%
|
0.58
|
| Long Term Debt And Capital Lease Obligation |
|
3.80
+0.00%
|
3.80
|
—
|
—
|
| Long Term Debt |
|
3.80
+0.00%
|
3.80
|
—
|
—
|
| Non Current Deferred Liabilities |
|
2.78
+61.17%
|
1.73
+50.00%
|
1.15
+100.00%
|
0.58
|
| Non Current Deferred Taxes Liabilities |
|
2.78
+61.17%
|
1.73
+50.00%
|
1.15
+100.00%
|
0.58
|
| Other Non Current Liabilities |
|
—
|
-0.00
|
—
|
—
|
| Stockholders Equity |
|
44.87
-2.76%
|
46.14
+80.69%
|
25.54
-29.59%
|
36.27
|
| Common Stock Equity |
|
44.87
-2.76%
|
46.14
+80.69%
|
25.54
-29.59%
|
36.27
|
| Capital Stock |
|
0.01
+16.72%
|
0.01
+6.00%
|
0.01
+0.00%
|
0.01
|
| Common Stock |
|
0.01
+16.72%
|
0.01
+6.00%
|
0.01
+0.00%
|
0.01
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
83.51
+16.72%
|
71.55
+0.44%
|
71.24
+0.00%
|
71.24
|
| Ordinary Shares Number |
|
83.51
+16.72%
|
71.55
+0.44%
|
71.24
+0.00%
|
71.24
|
| Additional Paid In Capital |
|
108.90
+27.50%
|
85.41
+95.63%
|
43.66
+4.71%
|
41.69
|
| Retained Earnings |
|
-64.04
-63.04%
|
-39.28
-116.65%
|
-18.13
-233.72%
|
-5.43
|
| Total Equity Gross Minority Interest |
|
44.87
-2.76%
|
46.14
+80.69%
|
25.54
-29.59%
|
36.27
|
| Total Capitalization |
|
48.67
-2.55%
|
49.94
+95.57%
|
25.54
-29.59%
|
36.27
|
| Working Capital |
|
-21.95
-1.00%
|
-21.73
-63.24%
|
-13.31
-321.73%
|
-3.16
|
| Invested Capital |
|
48.67
-2.55%
|
49.94
+95.57%
|
25.54
-29.59%
|
36.27
|
| Total Debt |
|
3.80
+0.00%
|
3.80
|
—
|
—
|
| Net Debt |
|
—
|
3.80
|
—
|
—
|
| Net Tangible Assets |
|
-28.53
-4.67%
|
-27.26
-88.46%
|
-14.46
-287.51%
|
-3.73
|
| Tangible Book Value |
|
-28.53
-4.67%
|
-27.26
-88.46%
|
-14.46
-287.51%
|
-3.73
|
| Dueto Related Parties Current |
|
9.51
+1515.77%
|
0.59
-96.98%
|
19.50
+315.44%
|
4.69
|
| Line Item | Trend | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-5.49
-4446.59%
|
0.13
|
0.00
|
0.00
|
| Cash Flow From Continuing Operating Activities |
|
-5.49
-4446.59%
|
0.13
|
0.00
|
0.00
|
| Net Income From Continuing Operations |
|
-24.76
-17.08%
|
-21.15
-66.56%
|
-12.70
-133.72%
|
-5.43
|
| Stock Based Compensation |
|
8.32
+10.96%
|
7.50
+281.52%
|
1.97
|
0.00
|
| Deferred Tax |
|
1.06
+83.50%
|
0.58
+0.00%
|
0.58
+0.00%
|
0.58
|
| Deferred Income Tax |
|
1.06
+83.50%
|
0.58
+0.00%
|
0.58
+0.00%
|
0.58
|
| Change In Working Capital |
|
9.89
-25.06%
|
13.20
+29.98%
|
10.16
+109.11%
|
4.86
|
| Change In Inventory |
|
-12.65
-492.78%
|
-2.13
|
0.00
|
—
|
| Change In Prepaid Assets |
|
0.00
+100.00%
|
-1.10
+78.19%
|
-5.04
-409.47%
|
-0.99
|
| Change In Payables And Accrued Expense |
|
22.54
+37.16%
|
16.43
+8.12%
|
15.20
+159.98%
|
5.85
|
| Change In Accrued Expense |
|
4.09
+1679.92%
|
-0.26
+67.69%
|
-0.80
-175.58%
|
1.06
|
| Change In Payable |
|
18.45
+10.51%
|
16.69
+4.32%
|
16.00
+234.36%
|
4.79
|
| Change In Account Payable |
|
9.52
+293.10%
|
2.42
+102.43%
|
1.20
+1196.42%
|
0.09
|
| Investing Cash Flow |
|
-5.75
-15.00%
|
-5.00
|
0.00
|
—
|
| Cash Flow From Continuing Investing Activities |
|
-5.75
-15.00%
|
-5.00
|
0.00
|
—
|
| Capital Expenditure |
|
-5.75
-15.00%
|
-5.00
|
—
|
—
|
| Net Intangibles Purchase And Sale |
|
-5.75
-15.00%
|
-5.00
|
0.00
|
—
|
| Purchase Of Intangibles |
|
-5.75
-15.00%
|
-5.00
|
0.00
|
—
|
| Financing Cash Flow |
|
15.17
+211.19%
|
4.87
|
0.00
|
—
|
| Cash Flow From Continuing Financing Activities |
|
15.17
+211.19%
|
4.87
|
0.00
|
—
|
| Net Issuance Payments Of Debt |
|
0.00
-100.00%
|
3.80
|
0.00
|
—
|
| Issuance Of Debt |
|
0.00
-100.00%
|
3.80
|
0.00
|
—
|
| Long Term Debt Issuance |
|
0.00
-100.00%
|
3.80
|
0.00
|
—
|
| Net Long Term Debt Issuance |
|
0.00
-100.00%
|
3.80
|
0.00
|
—
|
| Net Common Stock Issuance |
|
15.17
|
0.00
|
—
|
—
|
| Net Other Financing Charges |
|
—
|
1.07
|
—
|
—
|
| Changes In Cash |
|
3.92
+3504182.14%
|
0.00
|
—
|
—
|
| Beginning Cash Position |
|
0.00
|
0.00
|
0.00
|
0.00
|
| End Cash Position |
|
3.92
+3504282.14%
|
0.00
|
0.00
|
0.00
|
| Free Cash Flow |
|
-11.24
-130.67%
|
-4.87
|
0.00
|
0.00
|
| Common Stock Issuance |
|
15.17
|
0.00
|
—
|
—
|
| Issuance Of Capital Stock |
|
15.17
|
0.00
|
—
|
—
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-03-31 View
- 8-K2026-03-10 View
- 8-K2026-03-04 View
- 8-K2026-02-13 View
- 10-Q2026-02-13 View
- 8-K2025-12-23 View
- 10-K2025-12-23 View
- 8-K2025-12-10 View
- 8-K2025-12-01 View
- 8-K2025-10-27 View
- 8-K2025-10-23 View
- 42025-09-23 View
- 42025-09-23 View
- 42025-09-23 View
- 42025-09-23 View
- 42025-09-23 View
- 42025-09-23 View
- 42025-09-23 View
- 42025-09-23 View
- 42025-09-23 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|